Cisplatin and vinorelbine (PVn) for the treatment of advanced breast cancer: 10 years of experience.
Breast cancer is the most common malignancy in women throughout the world. It is the leading cause of cancer death of women aged > 50 years. Cisplatin and vinorelbine are active as single agents in advanced breast cancer but their combination was not studied before. We conducted three phase II trials using this combination in advanced breast cancer. Hereby, we describe our experience over a 10-year period at the American University of Beirut using this combination in metastatic disease as 1st and 2nd line therapy as well as in the neoadjuvant setting in patients with locally advanced disease. Our data will be compared with other groups using the same regimen for the management of advanced breast carcinoma.
Shamseddine
Ali
A
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. as04@aub.edu.lb
El-Saghir
Nagi
N
Chehal
Aref
A
Saliba
Teddy
T
Taher
Ali
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine